北方華創(002371.SZ)擬定增募資不超85億元 用於半導體裝備產業化基地擴產項目(四期)等等
格隆匯 4 月 21日丨北方華創(002371.SZ)披露2021年度非公開發行股票預案,擬非公開發行股票數量不超過1億股(含本數),該發行數量上限不超過截至預案公吿日公司總股本的20.14%。
募集資金總額不超過85億元,扣除發行費用後將用於“半導體裝備產業化基地擴產項目(四期)”、“高端半導體裝備研發項目”和“高精密電子元器件產業化基地擴產項目(三期)”的建設,並補充流動資金。此次發行的募集資金到位前,公司可根據市場情況利用自籌資金對募投項目進行先期投入,並在募集資金到位後予以置換。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.